Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lauri E Markowitz

Showing results (51-60 of 290) with videos related to

Pageof 29
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 27, 2018
Seroprevalence of Human Papillomavirus 6/11/16/18 Among Self-identified Gay/Bisexual Men Who Have Sex With Men, Men Who Have Sex With Women, and Females, United States, 2003-2010Rayleen M Lewis, Lauri E Markowitz, Gitika Panicker, et al.
The Journal of Infectious Diseases|August 31, 2015
Seroprevalence of 9 Human Papillomavirus Types in the United States, 2005-2006Gui Liu, Lauri E Markowitz, Susan Hariri, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2018
Seroprevalence of Herpes Simplex Virus Types 1 and 2 Among Pregnant Women and Sexually Active, Nonpregnant Women in the United StatesMonica E Patton, Kyle Bernstein, Gui Liu, et al.
Sexually Transmitted Diseases|September 16, 2003
Evaluation of syphilis reactor grids: optimizing impactJoshua K Schaffzin, Emilia H Koumans, Richard H Kahn, et al.
Vaccine|July 5, 2008
The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccinationHarrell W Chesson, Sara E Forhan, Sami L Gottlieb, et al.
Sexually Transmitted Diseases|September 16, 2016
Prevalence of 9-Valent Human Papillomavirus Types by Race/Ethnicity in the Prevaccine Era, United States, 2003-2006Gui Liu, Elizabeth R Unger, Susan Hariri, et al.
Annals of Internal Medicine|November 25, 2024
Cost-Effectiveness of Extending Human Papillomavirus Vaccination to Population Subgroups Older Than 26 Years Who Are at Higher Risk for Human Papillomavirus Infection in the United StatesJean-François Laprise, Harrell W Chesson, Lauri E Markowitz, et al.
Preventive Medicine|November 27, 2010
Human papillomavirus vaccine coverage in the United States, National Health and Nutrition Examination Survey, 2007-2008La'shan D Taylor, Susan Hariri, Maya Sternberg, et al.
Sexually Transmitted Diseases|September 24, 2009
Pre-treatment syphilis titers: distribution and evaluation of their use to distinguish early from late latent syphilis and to prioritize contact investigationsErika Samoff, Emilia H Koumans, James J Gibson, et al.
Vaccine|September 12, 2017
Human papillomavirus vaccination coverage using two-dose or three-dose schedule criteriaXia Lin, Loren Rodgers, Liping Zhu, et al.
Pageof 29

Showing results (51-60 of 290) with videos related to

Sort By:
Pageof 29
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 27, 2018
Seroprevalence of Human Papillomavirus 6/11/16/18 Among Self-identified Gay/Bisexual Men Who Have Sex With Men, Men Who Have Sex With Women, and Females, United States, 2003-2010Rayleen M Lewis, Lauri E Markowitz, Gitika Panicker, et al.
The Journal of Infectious Diseases|August 31, 2015
Seroprevalence of 9 Human Papillomavirus Types in the United States, 2005-2006Gui Liu, Lauri E Markowitz, Susan Hariri, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2018
Seroprevalence of Herpes Simplex Virus Types 1 and 2 Among Pregnant Women and Sexually Active, Nonpregnant Women in the United StatesMonica E Patton, Kyle Bernstein, Gui Liu, et al.
Sexually Transmitted Diseases|September 16, 2003
Evaluation of syphilis reactor grids: optimizing impactJoshua K Schaffzin, Emilia H Koumans, Richard H Kahn, et al.
Vaccine|July 5, 2008
The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccinationHarrell W Chesson, Sara E Forhan, Sami L Gottlieb, et al.
Sexually Transmitted Diseases|September 16, 2016
Prevalence of 9-Valent Human Papillomavirus Types by Race/Ethnicity in the Prevaccine Era, United States, 2003-2006Gui Liu, Elizabeth R Unger, Susan Hariri, et al.
Annals of Internal Medicine|November 25, 2024
Cost-Effectiveness of Extending Human Papillomavirus Vaccination to Population Subgroups Older Than 26 Years Who Are at Higher Risk for Human Papillomavirus Infection in the United StatesJean-François Laprise, Harrell W Chesson, Lauri E Markowitz, et al.
Preventive Medicine|November 27, 2010
Human papillomavirus vaccine coverage in the United States, National Health and Nutrition Examination Survey, 2007-2008La'shan D Taylor, Susan Hariri, Maya Sternberg, et al.
Sexually Transmitted Diseases|September 24, 2009
Pre-treatment syphilis titers: distribution and evaluation of their use to distinguish early from late latent syphilis and to prioritize contact investigationsErika Samoff, Emilia H Koumans, James J Gibson, et al.
Vaccine|September 12, 2017
Human papillomavirus vaccination coverage using two-dose or three-dose schedule criteriaXia Lin, Loren Rodgers, Liping Zhu, et al.
Pageof 29